Rafatian N, Milne RW, Leenen FH, Whitman SC. Role of reninangiotensin system in activation of macrophages by modified lipoproteins. Am J Physiol Heart Circ Physiol 305: H1309-H1320, 2013. First published August 30, 2013; doi:10.1152/ajpheart.00826.2012.-Angiotensin II favors the development of atherosclerosis. Our goal was to determine if foam cell formation increases angiotensin II generation by the endogenous renin-angiotensin system (RAS) and if endogenously produced angiotensin II promotes lipid accumulation in macrophages. Differentiated THP-1 cells were treated with acetylated low-density lipoproteins (ac-LDL), native LDL (n-LDL), or no LDL. Expression of RAS genes was assessed and angiotensin I/II levels were quantified in media and cell lysate. Ac-LDL increased angiotensin I/II levels and the angiotensin II/I ratio in cells and media after foam cell formation. Renin mRNA or activity did not change, but renin blockade completely inhibited the increase in angiotensin II. Angiotensinogen mRNA but not protein level was increased. Angiotensin-converting enzyme (ACE) and cathepsin G mRNA and activities were enhanced by ac-LDL. Inhibition of renin, ACE, or the angiotensin II receptor 1 (AT 1-receptor) largely abolished cholesteryl ester formation in cells exposed to ac-LDL and decreased scavenger receptor A (SR-A) and acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT-1) protein levels. Inhibition of renin or the AT 1-receptor in cells treated with oxidized LDL also decreased SR-A and ACAT-1 protein and foam cell formation. ac-LDL also increased angiotensin II by human peripheral blood monocyte-derived macrophages, whereas blockade of renin decreased cholesterol ester formation in these macrophages. These findings indicate that, during foam cell formation, angiotensin II generation by the endogenous RAS is stimulated and that endogenously generated angiotensin II is crucial for cholesterol ester accumulation in macrophages exposed to modified LDL. (6, 33, 34) . All components of the renin-angiotensin system (RAS) are present in atherosclerotic lesions (6). ANG II in atherosclerotic lesions localizes in macrophages (28). Human macrophages express all components of the RAS and release ANG II (25). Macrophages also express other enzymes that are able to produce ANG II such as cathepsin G, which can generate ANG II from either angiotensin I (ANG I) or angiotensinogen (29). Low-density lipoprotein (LDL) receptor-deficient atherosclerotic mice with renin deficiency in their bone marrow have reduced atherosclerotic lesion size, suggesting the importance of macrophage-derived ANG II in atherosclerosis (5).
THP-1 cells; angiotensin II; acetylated low-density lipoprotein; foam cells; cholesteryl ester ANGIOTENSIN II (ANG II) is an important modulator of the development and progression of atherosclerosis. Inhibition of the effects of ANG II by blocking angiotensin-converting enzyme (ACE) or the ANG II receptors decreases lesion progression in Apo E knockout (Apoe Ϫ/Ϫ ) mice (10, 12, 15) . ANG II receptor 1 (AT 1 receptor) deficiency in Apoe Ϫ/Ϫ and LDLr Ϫ/Ϫ atherosclerotic mice attenuates progression of atherosclerotic lesions, suggesting that AT 1 receptors mediate most of ANG II functions (6, 33, 34) . All components of the renin-angiotensin system (RAS) are present in atherosclerotic lesions (6) . ANG II in atherosclerotic lesions localizes in macrophages (28) . Human macrophages express all components of the RAS and release ANG II (25) . Macrophages also express other enzymes that are able to produce ANG II such as cathepsin G, which can generate ANG II from either angiotensin I (ANG I) or angiotensinogen (29) . Low-density lipoprotein (LDL) receptor-deficient atherosclerotic mice with renin deficiency in their bone marrow have reduced atherosclerotic lesion size, suggesting the importance of macrophage-derived ANG II in atherosclerosis (5) .
Lipid-laden macrophages are the predominant cell type in early stages of atherosclerosis (5) . Increased ANG II enhances foam cell formation (21, 38) through induction of enzymes involved in biosynthesis of cholesterol [3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase)] and cholesterol ester formation [acyl-coenzyme A cholesterol acyl transferase 1 (ACAT-1)] (13, 14) . ANG II also decreases cholesterol efflux by suppression of the ATP-binding cassette, subfamily A (ABCA1) transporter in macrophages (39) .
Although the expression of the RAS genes and ANG II release have been shown in macrophages (25) , changes in the expression of these genes and their effects on the final product of the system (ANG II ) have not yet been studied in foam cells. The role of locally generated ANG II in foam cell formation independently of circulating ANG II has also not yet been studied. In the present study we examined the hypothesis that 1) foam cell formation leads to an increase in expression of RAS genes and an increase in ANG II levels in lipid-laden macrophages, and 2) inhibition of ANG II formation decreases foam cell formation. We therefore evaluated 1) the effects of acetylated LDL treatment on expression of RAS genes and on ANG II levels, 2) the effects of renin inhibition on intra-and extracellular ANG II levels in acetylated LDL treated samples, and 3) the consequence of RAS inhibitor treatment on foam formation in phorbol-ester differentiated THP-1 cells coincubated with acetylated or oxidized LDL.
METHODS

Cell Cultures
THP-1 cells (a human acute monocytic leukemia cell line) from the American Type Culture Collection (ATCC TIB-202) were cultured in complete Roswell Park Memorial Institute medium 1640 (RPMI-1640) containing 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, 50 M ␤-mercaptoethanol, and 2 mM glutamine (Invitrogen, Burlington, ON, Canada). To differentiate these cells into macrophages, the monocytes were seeded in six-well plates at a density of 2-2.5 ϫ 10 6 cells/well in the same medium containing 100 nm phorbol 12-myristate 13-acetate (PMA) (Sigma, St Louis, MO) and incubated for 24 h. Differentiated macrophages were incubated for 24, 48, and 96 h in serum-free medium containing native LDL (n-LDL) or acetylated LDL (ac-LDL) (Biomedical Technologies, Stoughton, MA) at 50 g/ml (26) . Cholesteryl ester formation was also assessed in differentiated THP-1 cells treated with 50 g/ml oxidized LDL (ox-LDL) (Biomedical Technologies) (27) . To estimate the contribution of the scavenger receptor A (SR-A) to cholesteryl ester accumulation in ac-LDL-treated THP-1 cells, THP-1 cells were exposed to ac-LDL in the presence of 50 g·ml Ϫ1 ·day Ϫ1 of the SR-A ligands, dextran sulfate, or fucoidan (Sigma) (31) .
Human peripheral blood cells were collected from healthy volunteers. Monocytes were separated by gradient centrifugation using percol (GE Health Care Life Sciences, Quebec, Canada). Cells were washed with media and cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS, 100 units/ml penicillin and 100 g/ml streptomycin. Media were changed every 48 h up to 14 days.
Bone marrow cells were extracted from mouse femurs and tibias with DMEM containing 10% fetal bovine serum, 15% L929 condi- Cyclophilin A  5=-GTCAACCCCACCGTGTTCTT-3=  5=-CTGCTGTCTTTGGGACCTTGT-3=  Renin  5=-GCTTTCTCAGCCAGGACATC-3=  5=-TGGGAGATGATGTTGTCGAA-3=  ACE  5=-AGCATAGTACTGGTGACATCG-3=  5=-GACGATCTGGAACACCTCTAC-3=  Angiotensinogen  5=-GAAGAAGCCCTTCATCTTCC-3=  5=-GGAGAAGCCCTTCATCTTCC-3=  Cathepsin G  5=-ATAATCAGCGGACCATCCAG-3=  5=-CTGCCTATCCCTCTGCACTC-3= Primers were designed by primer 3 software and specificity was confirmed by Blast-n against total human gene bank. ACE, angiotensin-converting enzyme. tioned media, and 1% penicillin and streptomycin (Invitrogen). Cells were counted and plated at a concentration of 2 ϫ 10 6 cells/ml. Cells were differentiated to macrophages after 7 days incubation at 37°C. On day 7, cells were washed and medium was replaced by serum-free RPMI 1640 for lipoprotein treatment (27) .
A Positive
Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)
THP-1 cells were washed with ice-cold phosphate-buffered saline (PBS) and homogenized in TRIzol Reagent solution (Invitrogen) by repeated pipetting. Total RNA was isolated from cells according to the manufacturer's instructions. To eliminate potential genomic DNA contamination, total RNA was treated with DNase I (Ambion, Austin, TX) before the reverse transcription reaction. cDNA was synthesized using Superscript II RNase H Reverse Transcriptase (Invitrogen) at 42°C for 50 min. Real-time PCR amplifications were performed with a Roche Light Cycler by using Fast Start DNA Master SYBRGreen I (Roche Diagnostics, Penzberg, Germany). Two microliters of the RT product from each sample was used as a template at 20 l reaction. The specific primer sequences for angiotensinogen, ACE, renin, cathepsin G, SR-A, ACAT-1, and cyclophilin A are listed in Table 1 . The ACAT-1 primers that were used do not allow the differentiation between long and short ACAT transcripts (13) . The real-time PCR conditions were as follows: an initial step of 95°C for 10 min followed by 45 cycles of denaturation at 95°C for 5 s, and annealing of primers to the target for 5 s at 65°C for the renin primers, or 62°C for other primers. The extension step was performed at 72°C, and the extension time was determined by the formula: amplicon length/25 s. The specificity of real-time PCR products was documented with a melting curve analysis and high-resolution gel electrophoresis. The RT-PCR products of genes of interest were subcloned into pCRII TA vector (Invitrogen), followed by restriction endonuclease and sequencing analysis. The vector was transformed into E. coli bacteria strain DH5␣ for replication. The concentration of each construct was quantified by absorbance at 260 nm. Serial 10-fold dilutions of each plasmid clone were used to generate individual external standards with the same real-time PCR condition as described above. Expression of all genes was normalized to the cyclophilin A mRNA level as reference gene.
Angiotensin I and II Assay
Cell media were collected into 15-ml tubes containing EDTA-Na 2 and 1,10-phenantroline (inhibitor cocktail) (Sigma). After centrifugation, the media were immediately extracted on Sep-Pak C18 cartridges (Waters, Milford, MA). Cells were collected and washed with PBS then lysed in PBS containing the same inhibitor cocktail by sonication. Cell lysates were centrifuged and extracted on Sep-Pak 18 cartridges. Angiotensin peptides were assessed by radioimmunoassay (RIA) after separation on high-performance liquid chromatography (HPLC) (20, 22) .
Renin Activity
Five million cells were washed with PBS and lysed by sonication in 250 l of 0.2 M Tris buffer (containing 0.5 mM of EDTA-Na 2, phenylmethylsulfonyl fluoride, sodium tetrathionate dihydrate, and 0.1% Triton X-100). Lysates were centrifuged at 14,000 rpm and 4°C in an Eppendorf microfuge; 200 l of each supernatant was incubated for 1 h at 37°C with 250 l of renin substrate-enriched plasma from rats nephrectomized for 24 h. RIA for ANG I was done in duplicate on 200 l of the incubation mixture (21) . 
Cathepsin G Activity
Cells were harvested in PBS and washed with PBS. Protein was extracted from the cells by sonication of resuspended cells in assay buffer (1.5 M NaCl, 0.1 M Tris HCl, pH 7.4) plus Triton X-100 (Sigma). The reaction was carried out at 25°C in a total volume of 90 l: 20 l of sample plus 60 l of buffer (160 mM Tris/HCl and 1.6 M NaCl, pH 7.4) and 10 l N-succinyl-Ala-Ala-Pro-Phe-pNA as a substrate (20 mM in DMSO) (Sigma). The increase in absorbance at 410 nm due to the release of paranitroanilide per unit time is a measure for cathepsin G activity (2) .
Angiotensinogen Concentration
Angiotensinogen concentrations were determined by an in vitro enzyme kinetic assay (8) . Human angiotensinogen was completely exhausted by cleavage with excess human recombinant renin. Twentyfive microliters of lysate prepared from 5 million cells lysate was incubated together with 450 l of 1ϫ inhibitor cocktail (0.2 M Tris buffer containing: 0.5 mM of EDTA-Na 2, phenylmethylsulfonyl fluoride, sodium tetrathionate dihydrate and 0.1% Triton X-100) plus 1.0 pmol/ml of human recombinant renin (Sigma) for 1 h at 37°C. To measure angiotensinogen in media 250 l of media from 0.5 million cells were incubated with 250 l of 2ϫ-concentrated inhibitor cocktail plus 1.0 pmol/ml human recombinant renin. ANG I was measured by direct RIA. Angiotensinogen concentrations are expressed as picomoles per million cells based on an equimolar production of ANG I from angiotensinogen.
ACE Activity
Total protein from 1.25 ϫ 10 6 cells in 25 l of Tris-NaCl buffer containing 0.5% Triton X-100 (Sigma) was preincubated at 37°C for 20 min in the presence or absence of 100 M captopril (Sigma). To quantify ACE activity in media 25 l of media was used instead of cell lysate. Substrate, N-hippuryl-His-Leu hydrate (Sigma), was added to the mixture and, after incubation at 37°C for 1 h, the reaction was stopped with NaOH, and then o-phthaldialdehyde and HCl were added. Samples were centrifuged at 1,900 g at 4°C and 325 l of the supernatants were added to an opaque 96-well plate. His-Leu concentration was determined by measuring the fluorescence at wavelengths 360 nm excitation and 480 nm emission, using a Fluostar Galaxy fluorometer (BMG LABTECH, Durham, NC). The fluorescence of captopril-containing tubes was subtracted from those without captopril for each sample to have specific ACE activity. Activity was expressed as nanomoles His-Leu per minute per million cells (38) .
Cholesteryl Ester Measurement
Cells were washed with PBS and cholesterol was extracted by a 2-h incubation with isopropanol containing 1% Triton X-100. Dried isopropanol extracts were dissolved in the reaction mixture from Cholesterol/Cholesterol Ester Quantitation Kit (Biovision, Mountain View, CA). Free and total cholesterol were quantified based on the manufacturer's protocol. Cholesteryl ester concentration was quantified by deduction of free cholesterol from total cholesterol and is expressed as micrograms cholesterol per milligram protein.
Oil Red O Staining
THP-1 macrophages were plated in eight-chamber plates at 0.2 ϫ 10 6 cells per well and treated with ac-LDL as described above. Cells were washed twice with PBS, fixed with 4% (wt/vol) paraformaldehyde in PBS, and stained with Oil Red O in 60% (vol/vol) isopropyl alcohol, and hematoxylin.
Renin, ACE, Cathepsin G, and AT 1 Receptor Inhibition
To block the function of renin in THP-1 cells, lipoprotein-treated samples and controls were treated with 0, 100, 200 or 400 nM aliskiren, added once daily. Previous studies showed that a concentration of l00 nM aliskiren is required to block renin activity by 50% in human mast cells (19) . ANG II and cholesteryl ester were quantified in drug-and vehicle-treated samples.
Losartan at the concentration of 100 M was added once daily to block AT1 receptors. At this concentration losartan inhibits external ANG II-induced THP-1 cell migration toward endothelial cells (17) . Control and ac-LDL-treated samples were simultaneously treated with 100 M losartan or vehicle for 2 or 4 days. Cholesteryl ester formation was assessed in losartan-and vehicletreated samples.
To block ACE activity differentiated THP-1 cells were treated with 1 mM captopril or 5 M enalapril added once daily. Captopril at the concentration of 1 mM completely blocks ANG II generation induced by MCP-1 in rat mast cells (4) . Enalapril at 150 M completely inhibits tissue factor upregulation in coculture of human monocytic cells and human coronary artery endothelial cells (23) .
To block cathepsin G activity, the cathepsin G-specific inhibitor, CK-08, at a concentration of 5 M, was used (MP Biomedical, Solon, OH). At this concentration the proteolytic activity of cathepsin G for degrading, a human developmental nuclear factor is completely abolished. The inhibitor was added to the media every day (3).
To confirm that drug treatments do not affect cell viability and consequently other results, the number of viable cells after all drug treatments were counted with cell viability analyzer (Vi cell) (Beckman Coulter) (Fig. 1) . 
Western Blots
THP-1 cells were extracted by RIPA buffer, and protein concentrations were measured using the BCA assay (Fisher, Pittsburgh, PA). Twenty micrograms of protein was separated by nonreducing 10% SDS-polyacrylamide gel electrophoresis for SR-A and a reducing 10% SDS-polyacrylamide gel electrophoresis for ACAT-1. Migrated proteins were transferred to polyvinylidene fluoride (PVDF) membrane (300 mA for 2 h at 4°C). Membranes were blocked with 5% milk for 1 h and then incubated with rabbit anti-human ACAT-1 sc 20951 (Santa Cruz, CA), mouse anti-human SR-A MAB27081 (R&D System, Minneapolis, MN) or monoclonal ␤ actin antibody produced in mouse A2228 (Sigma) overnight at 4°C. Membranes were washed and based on the type of primary antibody; they were incubated with goat anti-rabbit horseradish peroxidase (HRP)-conjugated Sc 2004 (Santa Cruz) or anti-mouse Ig horseradish peroxidized linked whole antibody from sheep GRP NXA931 (GE Healthcare, UK) for 1 h at room temperature. The conversion of HRP substrate, Western Lightning Plus ECL NE 104001EA (Perkin Elmer, MA), was detected by digital imaging and analysis system (AlphaEase, Alpha Innotech; San Leandro, CA). Densitometric analysis of bands was performed with AlphaEase software. The density of ACAT-1 and SR-A bands was normalized to that of ␤-actin.
ELISA for TNF-␣
TNF-␣ was quantified in media by ELISA based on the manufacturer's protocol (Quantikine Human TNF␣ ELISA kit, R&D Systems, Minneapolis, MN).
Statistical Analysis
Values are means Ϯ SE. Comparisons were made using one-way ANOVA to compare different treated samples at a given time point or two-way ANOVA to compare treated samples at two different time points. All tests were performed using SigmaStat software (SPSS, Chicago, IL). The level of statistical significance was set at P Ͻ 0.05.
RESULTS
ac-LDL Increases ANG II Levels in THP-1 Cells
To examine the effects of modified lipoprotein uptake on ANG II levels in macrophages, differentiated THP-1 cells were treated with no LDL, n-LDL, or ac-LDL. After 2 days of treatment with ac-LDL, lipid droplets became visible in THP-1 cells. ANG I levels did not change after 1 day but significantly increased in both cell lysates and media after 2 days of treatment with ac-LDL by 100% in media and 80% in cells. ANG II levels remained elevated after 4 days of treatment with ac-LDL. n-LDL did not affect ANG II levels (Fig. 2, A and B) . ANG I levels increased by 50% after 2 days of treatment with ac-LDL and the increase persisted after 4 days (Fig. 2, C and D) . The ratio of ANG II/I was elevated in ac-LDL-treated samples around 1.5-fold both in media and cells after 2 days. At 4 days, the ratio of ANG II/I was still elevated with a slight but nonsignificant decrease relative to 2 days (Fig. 2, E and F) .
In human peripheral blood monocyte-derived macrophages, treatment with ac-LDL for 2 days also significantly increased ANG II formation (Fig. 3A) , although the extent appeared less than in THP-1 cells. In contrast, ac-LDL did not increase ANG II formation in mouse bone marrow-derived macrophages (for cells 1.9 Ϯ 0.5 vs. 
Expression of RAS Genes
Renin. Renin mRNA levels did not change after 1 or 2 days of treatment with ac-LDL (Fig. 4A) . Renin activity in THP-1 cell lysates also was not different (Fig. 5A) .
Angiotensinogen. One-day treatment with ac-LDL did not change the mRNA level of angiotensinogen in THP-1 cells, but 2 days of treatment increased angiotensinogen mRNA levels significantly (by 90%) compared with nontreated and n-LDLtreated samples (Fig. 4B) . n-LDL did not affect mRNA levels. The increase in the mRNA level in ac-LDL treated cells did not, however, result in a higher angiotensinogen concentration in media or cells, as assessed by the kinetic assay (Fig.  5, E and F) .
ACE. ac-LDL treatment for 1 day caused a significant increase in ACE mRNA levels (by ϳ60%) in THP-1 cells relative to nontreated and n-LDL-treated samples. ACE mRNA levels remained elevated after 2 days of treatment with ac-LDL (Fig. 4C) . n-LDL did not change ACE expression. ACE activity was increased in media and cell lysates after 2 days of ac-LDL by 60% and 40% relative to controls, respectively (Fig. 5, C and D) .
Cathepsin G. mRNA levels in treated and nontreated samples were similar after 1 day of treatment, but both ac-LDL and n-LDL significantly increased cathepsin G expression in THP-1 cells after 2 days of treatment (Fig. 4D) . There was also no difference in cathepsin G activity in cell lysates after 1 day, but cathepsin G activity was significantly increased after 2 days in ac-LDL-treated THP-1 cells vs. control and n-LDL-treated cells (Fig. 5B) .
Role of Renin in ANG II Production
The renin inhibitor, aliskiren, at concentrations of 100 and 200 nM reduced ANG II production by 60% and 70%, respectively. The concentration of 400 nM completely blocked ANG II production in nontreated and ac-LDL-treated samples (Fig. 6 ). This finding is consistent with a key role of renin in production of ANG II from angiotensinogen in THP-1 cells. We could not assess the effect of ACE inhibition on ANG II production in our model since the inhibitors interfered with the radioimmunoassay measurement. We were also not able to determine the role of cathepsin G in ANG II production due to toxicity of long-term exposure of cells to the cathepsin G inhibitor.
ANG II and Foam Cell Formation
Blockade of ANG II formation by treatment of THP-1 cells with ac-LDL and the renin inhibitor aliskiren decreased cholesteryl ester formation after 2 days by 95% without changing cell viability (Figs. 1 and 7A) . The cholesteryl ester content of cells was further increased by 4 days of ac-LDL treatment compared with 2 days of treatment, but in cells exposed to 4 days of ac-LDL with aliskiren cholesteryl content was reduced by 96% relative to non-aliskiren-treated cells (Fig. 7A) . Blocking AT 1 receptors by losartan also abolished cholesteryl ester formation in ac-LDL-treated samples both at 2 days and 4 days (Fig. 7B) . The ACE inhibitors captopril and enalapril reduced cholesteryl ester content of the ac-LDL-treated cells by 80% (Fig. 7, C and D) .
To assess whether ANG II is also involved in cholesteryl ester accumulation in ox-LDL-treated THP-1 cells, THP-1 cells were exposed to ox-LDL, either alone, or together with losartan or aliskiren. Both losartan and aliskiren prevented the cholesteryl ester formation in ox-LDL-treated cells (Fig. 8A) , suggesting a general role of ANG II in accumulation of cholesteryl ester in modified LDL-treated macrophages. In human peripheral blood monocyte-derived macrophages, renin blockade by aliskiren also decreased the cholesterol ester content of ac-LDL-treated macrophages by 30% (Fig. 3B) .
These effects of RAS blockade did not appear to be the result of changes in TNF-␣ levels. THP-1 cells were, or were not, exposed to ac-LDL in the presence or absence of the renin inhibitor, aliskiren, for 48 h, and TNF-␣ was then measured in the media (Fig. 9) . Aliskiren did not affect the TNF␣ levels in the media of cells that had or had not been treated with ac-LDL.
RAS Inhibitors and Expression of SR-A and ACAT-1
Blocking SR-A by an excess of the SR-A ligands, fucoidan or dextran sulfate, significantly reduced the cholesteryl ester content of ac-LDL-treated cells, which suggests that SR-A is a major pathway for ac-LDL uptake (Fig. 8B) . To assess the effects of RAS inhibitors on SR-A and ACAT-1, the enzyme responsible for cholesteryl esterification in macrophages, cell extracts from THP-1 cells treated with ac-LDL with or without aliskiren, losartan, captopril or enalapril were subjected to Western blot. Treatment with ac-LDL for 2 days significantly increased SR-A and ACAT-1 protein levels by ϳ30% (Fig. 10, A and B) . All RAS blockers similarly prevented the increase in SR-A protein. For ACAT-1, the blockers not only prevented the increase in ACAT-1 immunoreactive protein induced by ac-LDL, but significantly decreased ACAT-1 protein levels below those of the control (Fig. 10B) . In contrast to ac-LDL treatment, exposure of THP-1 cells to ox-LDL decreased immunoreactive SR-A but did not change ACAT-1. SR-A protein in ox-LDL-treated cells was further reduced by both losartan and aliskiren (Fig. 10C) . Losartan and aliskiren also reduced immunoreactive ACAT-1 protein in THP-1 cells treated with ox-LDL (Fig. 10D) .
To assess whether RAS inhibition downregulates SR-A and ACAT-1 also at the mRNA level, the mRNA levels were measured using real-time qRT-PCR. Neither ac-LDL nor ox-LDL affected SR-A or ACAT-1 mRNA levels (Fig. 11) . Losartan or aliskiren did not change the SR-A mRNA level in ac-LDL-treated THP-1 cells but, in ox-LDL-treated cells, the RAS inhibitors reduced SR-A mRNA (Fig. 11B) . Unexpectedly, ACAT-1 mRNA was increased by RAS inhibitors in ac-LDL-treated cells (Fig. 11C) . ACAT-1 mRNA in ox-LDLtreated cells was not measured.
DISCUSSION
The present study shows as new findings that treatment of THP-1 macrophages with ac-LDL increases ANG I and II levels and the ANG II to ANG I ratio in both cell lysates and media, associated with increased levels of ACE and cathepsin G mRNA and enzyme activities. Although renin mRNA and activity levels do not change in cells exposed to ac-LDL, renin is essential for ANG II formation as the renin inhibitor, aliskiren completely abolishes ANG II production in both ac-LDL-treated and nontreated cells. Inhibition of this endogenously generated ANG II with renin, ACE, or AT 1 receptor blockers attenuates cholesteryl ester formation in ac-LDLtreated cells. Importantly, ANG II is not only required for ac-LDL-induced foam cell formation but also for the stimulation of cholesteryl ester formation in THP-1 cells exposed to the more physiologically relevant, modified lipoprotein, ox-LDL. ANG II may promote both lipoprotein uptake by increas- ing SR-A protein and cholesterol esterification by increasing ACAT-1 protein. In a milieu where macrophages are exposed to modified lipoproteins such as the arterial wall, the combination of increased generation of ANG II and the ability of ANG II to promote the accumulation of cholesteryl esters may amplify foam cell formation and thus contribute to atherogenesis.
Modulation of Endogenous RAS During Foam Cell Formation
Treatment of differentiated THP-1 cells with ac-LDL increased angiotensinogen, cathepsin G, and ACE mRNA levels, whereas renin expression was not changed. While we did not explore the molecular mechanisms responsible for the increase of these mRNAs in the presence of ac-LDL, a number of transcription factors and signaling pathways have been implicated in regulation of genes encoding components of RAS including early growth response-1 which is important in both foam cell formation (16) and ACE gene expression (7) and hypoxia inducible factor-1␣ (32), whose activation in human monocytes can be triggered by ox-LDL and which activates ACE gene expression (37) . In addition, binding of ANG II to the AT 1 receptor triggers a signaling pathway leading to nuclear factor kappa B-activated transcription of the angiotensinogen gene initiating a positive feedback loop (30) . Any or all of these pathways could be implicated in the increased mRNA level encoding proteins involved in ANG II formation.
ac-LDL treatment increased ANG I and II content of THP-1 cells and media by 50% and 100%, respectively. As noted above, renin mRNA expression and activity did not change in the treated cells, but renin activity is essential for ANG II generation since renin blockade completely abolished ANG II in ac-LDL-treated and nontreated THP-1 cells. The complete blockade of ANG II production in aliskiren-treated samples rules out a role of cathepsin D in conversion of angiotensinogen to ANG I and the direct generation of ANG II from angiotensinogen by cathepsin G or by other enzymes. Moreover, Whatling et al. (35) reported that cathepsin D is not increased in foam cells. Angiotensinogen mRNA was increased 2 days after ac-LDL treatment, but this was not reflected in the angiotensinogen protein level. This dissociation might be due to increased turnover of angiotensinogen protein.
Depending on the actual renin and angiotensinogen concentrations, either can be rate-limiting for the generation of ANG I (18) . In THP-1 cells angiotensinogen might be rate-limiting for the production of angiotensin peptides and the absence of an increase in angiotensinogen protein might be due to faster consumption. For ACE, both mRNA and enzyme activities increased in ac-LDL-treated THP-1 cells, consistent with a study by Diet et al. (6a) . The ϳ50% increase in ACE activity likely promotes the conversion rate of ANG I to ANG II, contributing to the ϳ1.5-fold higher ratio of ANG II to ANG I in cells to ac-LDL. Increased renin-dependent conversion of angiotensinogen together with enhanced ACE activity appear therefore to be responsible for the augmented ANG I and II generation in THP-1 cells during their transformation to foam cells. Cathepsin G mRNA and activity also increased, but due to toxicity of cathepsin G inhibitors, we could not directly test the contribution of cathepsin G to ANG II generation.
Role of ANG II in Foam Cell Formation
Our results suggest that macrophage-derived ANG II binds to the AT 1 receptor and activates a signaling pathway that is required for cholesteryl ester accumulation in cells exposed to ac-LDL. or mice treated with losartan and ramipril, respectively (11, 12) . Thus the endogenous RAS appears to be required for foam cell formation mediated by multiple cell surface receptors for modified lipoproteins. ANG II has been reported to influence cholesteryl ester accumulation in macrophages by altering cholesterol efflux (39) and cholesterol synthesis (14) . However, under the experimental conditions used in the present study (the absence of cholesterol acceptors and exposure of the cells to ac-LDL), it is unlikely that either reduced cholesterol efflux or enhanced cholesterol synthesis could explain the profound effects of endogenous ANG II on ac-LDL-induced cholesteryl ester accumulation in THP-1 cells. Rather, we present evidence that endogenous ANG II promotes modified lipoprotein uptake and cholesterol esterification by upregulating the levels of SR-A and ACAT-1, respectively. SR-A protein levels are increased in THP-1 cells exposed to ac-LDL and this is prevented by RAS inhibition. Exposure of THP-1 cells to ox-LDL decreases immunoreactive SR-A, and SR-A protein is further reduced by aliskiren and losartan treatment. The downregulation of SR-A protein by ox-LDL could reflect the reciprocal regulation of SR-A and CD36 expression or the degree of oxidation of the LDL and its content of specific oxidized lipids, both of which have been shown to affect SR-A expression (9, 24, 36) . In the case of THP-1 cells treated with ox-LDL (but not in cells treated with ac-LDL), RAS inhibition may downregulate gene expression as the lower SR-A protein levels are coupled with lower SR-A mRNA levels.
Like SR-A, ACAT protein levels in THP-1 cells treated with modified LDL are decreased by RAS inhibition, and this appears to be independent of gene expression as ACAT mRNA levels are actually increased in cells treated with aliskiren and losartan. Kanome et al. (13) reported that exogenous ANG II increases a shorter form of ACAT-1 mRNA and elevates ACAT-1 protein levels in peripheral blood monocyte-derived macrophages. It should be noted that, in the present study, we used primers that would detect all ACAT-1 transcripts and would not differentiate the shorter transcript that was shown to be increased by ANG II treatment in the study of Kanome et al. effect was independent of endogenously generated ANG II but rather resulted from the ability of AT 1 receptor blockers to reduce epidermal growth factor receptor activation by ox-LDL. The discrepancy with the present study in terms of the role of the endogenous RAS likely reflects differences in experimental conditions between the two studies as we clearly demonstrate the importance of ANG II generation by the endogenous RAS in foam cell formation.
On the basis of our results, we propose a model in which exposure of THP-1 cells to ac-LDL upregulates the RAS, leading to increased generation of ANG II. ANG II, in turn, binds to the AT 1 receptor and activates a signaling cascade that results in increased synthesis or reduced catabolism of SR-A and ACAT-1 and, as a consequence, enhanced cholesteryl ester accumulation. The ability of renin, ACE, and AT 1 blockers to break this positive feedback loop may contribute to their well-documented antiatherogenic properties.
Limitations of Study
First, cell lines are powerful experimental models to study basic cellular mechanism. However, the cell line per se and cell culture conditions can influence these mechanisms, and it is important to consider that such studies are only "hypothesisgenerating" toward understanding the actual cellular mechanisms in the intact animal. Nonetheless, the general concept emerging from our studies is clearly consistent with the large body of work on the role of ANG II in the development of atherosclerosis in animals and humans (see Introduction). Second, the primary findings in THP-1 cells and human monocytederived macrophages are qualitatively quite similar, i.e., ac-LDL increases ANG II production and renin blockade inhibits ac-LDL-induced cellular cholesteryl ester accumulation in both cell types. However, the extent of these changes appears more pronounced in the THP-1 cells. The relevance of these quantitative differences between the two cell types for in vivo regulation is difficult to ascertain. 
